newsfilter
← Latest News
GlobeNewswire·

Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026Pivotal phase 3 clinical data published in The